IPO Boutique

Omthera Pharmaceuticals IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on Omthera Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
Omthera PharmaceuticalsOMTH -
NASDAQ
$12.00-$14.00 $8.00 $7.408 million4/11/2013
BofA Merrill Lynch, Barclays Capital, Leerink Swann
Co-Manager(s):
Stifel Nicolaus Weisel, Piper Jaffray
Health Care
Filing(s):

Filed 2013-03-11



Omthera Pharmaceuticals Quote & Chart - Click for current quote - OMTH

About Omthera Pharmaceuticals (adapted from Omthera Pharmaceuticals prospectus):
They are an emerging specialty pharmaceutical company focused on the development and commercialization of new therapies for abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular disease. Epanova, currently their sole product candidate, is a late-stage, novel, omega-3 free fatty acid composition that meaningfully reduces triglycerides, improves other key lipid parameters and is expected to increase patient convenience with 2-gram once-a-day dosing with or without meals.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as "OMTH" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved